LGL Group (NYSEAMERICAN:LGL) Issues Earnings Results

LGL Group (NYSEAMERICAN:LGL) posted its quarterly earnings results on Monday. The industrial products company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.09), reports. LGL Group had a net margin of 16.50% and a return on equity of 1.66%. The business had revenue of $0.80 million during the quarter, compared to the consensus estimate of $9.10 million.

LGL Group Stock Performance

NYSEAMERICAN:LGL traded up $0.15 during trading hours on Wednesday, reaching $7.10. The company’s stock had a trading volume of 3,447 shares, compared to its average volume of 12,499. The stock has a 50 day moving average price of $7.14 and a two-hundred day moving average price of $6.48. The company has a market capitalization of $46.36 million, a P/E ratio of 64.55 and a beta of 0.31. LGL Group has a 12 month low of $5.45 and a 12 month high of $9.74.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in LGL Group stock. Citadel Advisors LLC acquired a new position in shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned about 0.25% of LGL Group at the end of the most recent reporting period. 30.28% of the stock is currently owned by institutional investors and hedge funds.

LGL Group Company Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.